Abstract: Subject matter of the invention are antibody-cytokine fusion proteins having proapoptotic and immune modulating properties, but wherein the cytokine moiety a priori has a bioactivity which is very low or restricted to certain receptor subtypes. These reagent exert their full biological activity via the corresponding cytokine receptor(s) only after antibody-mediated binding of the fusion protein to a specific cell membrane-expressed target molecule. By suitable choice of the antibody specificity, the cytokine activity is directed to the tissue, e.g. tumour tissue, to be treated, and a therapeutic agent can be produced being specifically designed/optimised for the respective indication/tumour entity.

Abstract: An elevator installation includes an elevator cage with a support construction carrying the elevator cage, wherein the support construction has two beams. Mounted on each beam is a positioning arrangement on which a sensor is positioned, which is part of a load measuring device, wherein the positioning arrangements have material structures. The sensors detect a change in spacing of the material structures from one another, wherein this change in spacing is caused by a change in loading of the elevator cage. Signals of the sensors are processed in an evaluating unit and a signal representing the loading is used in an elevator control.

Abstract: A connecting element connects a first wall panel with a second wall panel. A first spring element is supported on the upper part of the connecting element and on one side of a first bend. A second spring element is supported on the upper part and on one side of a second bend. The other side of the second bend presses on one side of the first bend. The connecting element is introduced without a tool into a first slot of the first bend and the second bend is placed at a second slot over the connecting element.

Abstract: An elevator cage is movable in an elevator shaft, wherein a ventilating device is fastened to a cage outer surface, wherein this ventilating device forms at least one ventilation channel, wherein the at least one ventilation channel has at least one primary ventilation opening enabling an air exchange between the ventilation channel and the elevator shaft, wherein at least one of the cage outer surfaces has at least one secondary ventilation opening enabling an air exchange between a cage interior space and the at least one ventilation channel, with at least one element of insulating material, and wherein the at least one element substantially determines a path of the at least one ventilation channel.

Abstract: A support frame has at one or more lower cage corners a respective support, at which at least one damping element is arranged. The support has a U-shaped cross-section and can be inserted into a beam with C-shaped cross-section. The elevator cage is mounted on the damping elements, which can keep oscillations and vibrations away from the elevator cage. Near the inserted support, a device can be provided for raising the elevator cage if the support or at least one damping element has to be replaced.

Abstract: An elevator installation includes an elevator cage with a support construction carrying the elevator cage, wherein the support construction has two beams. Mounted on each beam is a positioning arrangement on which a sensor is positioned, which is part of a load measuring device, wherein the positioning arrangements have material structures. The sensors detect a change in spacing of the material structures from one another, wherein this change in spacing is caused by a change in loading of the elevator cage. Signals of the sensors are processed in an evaluating unit and a signal representing the loading is used in an elevator control.

Abstract: An elevator cage floor has a composite-structure or sandwich mode of construction, including at least one base plate, at least one top plate and at least one composite-structure core disposed therebetween and having at least two chambers, wherein the composite-structure core is connected with the base plate and the top plate. At least one of the at least two chambers of the composite-structure core is at least partly filled with a defined amount of a filler.

Abstract: A floor for an elevator cage has a base plate, a top plate and a support structure arranged therebetween. The support structure comprises a grating arrangement including a plurality of intersecting profile members standing on edge. For local reinforcement, the support structure additionally includes a second grating arrangement superimposed on the first arrangement.

Abstract: An elevator installation includes an elevator cage with a support construction carrying the elevator cage, wherein the support construction has two beams. Mounted on each beam is a positioning arrangement on which, for example, a sensor is positioned, which is part of a load measuring device, wherein the positioning arrangements have material structures or sensor carriers. The sensors detect a change in spacing of the material structures or of the sensor carriers from one another, wherein this change in spacing is caused by a change in loading of the elevator cage. Signals of the sensors are processed in an evaluating unit and a signal representing the loading is used in an elevator control.

Abstract: Subject matter of the invention are antibody-cytokine fusion proteins having proapoptotic and immune modulating properties, but wherein the cytokine moiety a priori has a bioactivity which is very low or restricted to certain receptor subtypes. These reagent exert their full biological activity via the corresponding cytokine receptor(s) only after antibody-mediated binding of the fusion protein to a specific cell membrane-expressed target molecule. By suitable choice of the antibody specificity, the cytokine activity is directed to the tissue, e.g. tumour tissue, to be treated, and a therapeutic agent can be produced being specifically designed/optimised for the respective indication/tumour entity.

Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to Fibroblast Activation Protein (FAP) are provided, particularly recognizing both human and mouse FAP. These antibodies are useful in the diagnosis and treatment of conditions associated with activated stroma, including wound healing, epithelial cancers, osteoarthritis, rheumatoid arthritis, cirrhosis and pulmonary fibrosis. The anti-FAP antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies ESC1 1 and ESC 14 whose sequences are provided herein.

Abstract: Subject matter of the invention are antibody-cytokine fusion proteins having proapoptotic and immune modulating properties, but wherein the cytokine moiety a priori has a bioactivity which is very low or restricted to certain receptor subtypes. These reagent exert their full biological activity via the corresponding cytokine receptor(s) only after antibody-mediated binding of the fusion protein to a specific cell membrane-expressed target molecule. By suitable choice of the antibody specificity, the cytokine activity is directed to the tissue, e.g. tumor tissue, to be treated, and a therapeutic agent can be produced being specifically designed/optimized for the respective indication/tumor entity.

Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to Fibroblast Activation Protein (FAP) are provided, particularly recognizing both human and mouse FAP. These antibodies are useful in the diagnosis and treatment of conditions associated with activated stroma, including wound healing, epithelial cancers, osteoarthritis, rheumatoid arthritis, cirrhosis and pulmonary fibrosis. The anti-FAP antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies ESC1 1 and ESC 14 whose sequences are provided herein.

Abstract: A floor for an elevator cage has a base plate, a top plate and a support structure arranged therebetween. The support structure comprises a grating arrangement including a plurality of intersecting profile members standing on edge. For local reinforcement, the support structure additionally includes a second grating arrangement superimposed on the first arrangement.

Abstract: A connecting element connects a first wall panel with a second wall panel. A first spring element is supported on the upper part of the connecting element and on one side of a first bend. A second spring element is supported on the upper part and on one side of a second bend. The other side of the second bend presses on one side of the first bend. The connecting element is introduced without a tool into a first slot of the first bend and the second bend is placed at a second slot over the connecting element.

Abstract: An elevator cage is movable in an elevator shaft, wherein a ventilating device is fastened to a cage outer surface, wherein this ventilating device forms at least one ventilation channel, wherein the at least one ventilation channel has at least one primary ventilation opening enabling an air exchange between the ventilation channel and the elevator shaft, wherein at least one of the cage outer surfaces has at least one secondary ventilation opening enabling an air exchange between a cage interior space and the at least one ventilation channel, with at least one element of insulating material, and wherein the at least one element substantially determines a path of the at least one ventilation channel.

Abstract: An elevator cage floor has a composite-structure or sandwich mode of construction, including at least one base plate, at least one top plate and at least one composite-structure core disposed therebetween and having at least two chambers, wherein the composite-structure core is connected with the base plate and the top plate. At least one of the at least two chambers of the composite-structure core is at least partly filled with a defined amount of a filler.

Abstract: An elevator installation includes an elevator cage with a support construction carrying the elevator cage, wherein the support construction has two beams. Mounted on each beam is a positioning arrangement on which, for example, a sensor is positioned, which is part of a load measuring device, wherein the positioning arrangements have material structures or sensor carriers. The sensors detect a change in spacing of the material structures or of the sensor carriers from one another, wherein this change in spacing is caused by a change in loading of the elevator cage. Signals of the sensors are processed in an evaluating unit and a signal representing the loading is used in an elevator control.

Abstract: A support frame has at one or more lower cage corners a respective support, at which at least one damping element is arranged. The support has a U-shaped cross-section and can be inserted into a beam with C-shaped cross-section. The elevator cage is mounted on the damping elements, which can keep oscillations and vibrations away from the elevator cage. Near the inserted support, a device can be provided for raising the elevator cage if the support or at least one damping element has to be replaced.

Abstract: Subject matter of the invention are antibody-cytokine fusion proteins having proapoptotic and immune modulating properties, but wherein the cytokine moiety a priori has a bioactivity which is very low or restricted to certain receptor subtypes. These reagent exert their full biological activity via the corresponding cytokine receptor(s) only after antibody-mediated binding of the fusion protein to a specific cell membrane-expressed target molecule. By suitable choice of the antibody specificity, the cytokine activity is directed to the tissue, e.g. tumour tissue, to be treated, and a therapeutic agent can be produced being specifically designed/optimised for the respective indication/tumour entity.